To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: α-hemolysin (aHL) Patent application filed; unavailable for licensing

Infectious disease

INDICATION: Bacterial infection

In vitro and mouse studies suggest a mAb against multiple Staphylococcus aureus hemolysin

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE